App-Based lifestyle coaching aims to cut dementia risk in older adults

NCT ID NCT04616794

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study tests a coach-assisted mobile app designed to help middle-aged and older adults adopt healthier habits—like being more physically active, eating a Mediterranean diet, and staying mentally engaged—to reduce their risk of dementia. Participants with at least one modifiable risk factor (such as low physical activity or low cognitive engagement) will use the app to set goals and receive tailored guidance. The study will measure whether at least half of participants show meaningful improvements in these lifestyle behaviors by the end of the program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A coach-assisted mobile application delivering tailored, multidomain lifestyle interventions (physical activity, diet, cognitive engagement)
What this could lead to
If successful, this app-based approach could offer a scalable way to help older adults reduce their dementia risk through lifestyle changes.
What could go wrong
This is a small proof-of-concept study, so results may not generalize. Success depends on participants' adherence, and the app's impact on long-term dementia risk remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Oct 2020

Finished

Jan 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Proficient or native speakers in French; * Computer literate; * Committed not to participate in another program related to any of the three intervention domains for the duration of the trial; * At least one of the following: * Low cognitive engagement in cognitively stimulating activities, defined as a score ≤ 15 on the CAQ * Low level of physical activity defined as less than 600 MET-min/week (\~150 minutes/week) of MVPA measured using the IPAQ-SF * Low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian MDS Exclusion Criteria * Presence of a cognitive impairment as measured by the Cogstate Brief BatteryTM ; * General anesthesia within the last 6 months; * Participation in any previous validation studies related to the program; * Participation, currently or within the last 6 months, in a program where they received any of the three interventions; * Unable to commit participation over the period of the study. * Participants in the precontemplation stage of change. * Participants with a high level of perceived stress. * Having received a diagnosis of: * Dementia or neurodegenerative disease; * Past or present neurological disorder; * Severe psychiatric disorder; * Uncontrolled cardiovascular or metabolic diseases; * Alcoholism or drug addiction; * Any other conditions expected to limit participation. Domain-Specific exclusion criteria * Participants will be excluded from the physical activity intervention, but not the trial, if they have a medical contraindication to physical activity based on the Physical Activity Readiness Questionnaire * Individuals with dietary restrictions due to medical reasons, allergies or severe intolerance or an history of eating disorders will be excluded from participation in the healthy diet intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Risk-Taking dementia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sylvie Belleville

    Montreal, Quebec, H3W 1W5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.